Clinical trials: Heart Transplant Rejection
Cardiac Transplantation
Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs
The purpose of this study is to evaluate the level of expression of 4 circulating microRNAs in the serum using RT-PCR. A pilote study with cardiac transplant patients has shown that expression of these microRNAs could…
- Trial name
- MIRRACLE (NCT02672683)
- Where
- France
- Volunteers
- 461 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Transplantation, Rejection Heart Transplant
Evaluation of the Added Clinical Value of Donor-derived Cell-free DNA for the Monitoring of Cardiac Allograft Rejection.
The goal of this observational study is to assess the clinical added value of donor-derived cell-free DNA (dd-cfDNA) to monitor cardiac allograft rejection.
- Trial name
- HEART-FREE (NCT06740578)
- Where
- 2 sites in France
- Volunteers
- 320 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Advanced Heart Failure, Heart Transplantation
Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study
The purpose of this research study is to apply new non-invasive, no-risk techniques to a cardiac transplant population for assessment of their reliability in detecting heart transplant rejection.
- Trial name
- NCT00572286
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Failure, Liver Fibrosis
Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
Magnetic resonance elastography is a novel non-invasive MRI technique to obtain stiffness of soft tissues such as liver, heart, kidneys, etc.
- Conditions
- Heart Failure, Liver Fibrosis, Cardiac Transplant Rejection, Aortic Aneurysms
- Trial name
- MRE (NCT01757730)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Arunark Kolipaka
Heart Transplant Rejection
A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation
This study is a prospective, observational multi-center cohort study. The study will consist of patients undergoing heart transplantation.
- Trial name
- BIODRAFT (NCT03477383)
- Testing
- donor-derived cell-free DNA (dd-cfDNA)
- Where
- 4 sites in Sweden
- Volunteers
- 134 people
- Sponsor
- Vastra Gotaland Region
Graft Rejection, Heart Transplantation
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
The a series of clinical studies of [18F]FSPG PET/CT showed that [18F]FSPG is safe and promising PET tracer for detecting inflammation with favorable biodistribution and pharmacokinetics in patients.
- Conditions
- Graft Rejection, Heart Transplantation, Liver Transplantation
- Trial name
- NCT04488094
- Testing
- [18F]FSPG
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Asan Medical Center
Heart Transplantation, Kidney Transplantation
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
Activity of genes in donor tissues that are involved in inflammation are thought to be involved with early organ dysfunction, increased immune responses in transplant recipients, and organ rejection.
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
- Trial name
- NCT00531921
- Where
- 5 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Transplantation, End-stage Heart Failure
Donor Circadian Rhythm and Its Correlation With Prognosis After Heart Transplantation
The goal of this observational study is to learn about the impact of donor heart procurement time based on circadian rhythm on the long-term outcomes of heart transplant recipients.
- Conditions
- Heart Transplantation, End-stage Heart Failure, Circadian Rhythm
- Trial name
- CIRCA-HTx (NCT07301788)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cardiac Transplant Failure, Cardiac Transplant Rejection
Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Trial name
- D-OAR (NCT02178943)
- Where
- 28 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CareDx
Allosensitization, Heart Transplant Failure and Rejection
Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation.
- Trial name
- NCT04610320
- Testing
- Daratumumab-SC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ronald Witteles
Heart Transplant Failure and Rejection
Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation
Evaluate the association between donor soluble protein ST2 (sST2) serum levels and 30-day recipient mortality in order to improve graft screening.
- Trial name
- ISIDORE (NCT03050892)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Renal Transplantation, Heart Transplantation
Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation
The primary objective is to investigate intralymphocyte concentrations of CsA in renal and heart transplant recipients to elucidate the association between the intracellular concentration and efficacy (rejection episodes and…
- Trial name
- NCT00139009
- Testing
- Cyclosporine A
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- University of Oslo School of Pharmacy
Cardiac Allograft Vasculopathy, Heart Transplant Rejection
Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy
Heart transplantation is a golden standard for the treatment of terminal heart failure. The major cause of death in late posttransplant period is cardiac allograft vasculopathy (CAV).
- Trial name
- ECP-OCT (NCT04226521)
- Testing
- Extracoropreal photopheresis
- Where
- Croatia
- Volunteers
- 38 people
- Sponsor
- Bosko Skoric
Heart Transplant Rejection
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart…
- Trial name
- ProTECT (NCT05205551)
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Natera, Inc.
Allosensitization, Heart Transplant Failure and Rejection
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
The purpose of this study is to test whether daratumumab, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation.
- Trial name
- NCT04088903
- Testing
- Daratumumab
- Sponsor
- Ronald Witteles
Cardiac Transplant Disorder, Cardiac Death
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Heart transplantation (HTx) is a procedure which is hindered by several complications. The HEARTS registry aims to allow the analysis of risk factors of all post-HTx complications.
- Conditions
- Cardiac Transplant Disorder, Cardiac Death, Heart Failure, Acute Cellular Graft Rejection
- Trial name
- HEARTS (NCT03393793)
- Volunteers
- 566 people
- Sponsor
- Lee S Nguyen
Heart Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant.
- Trial name
- NCT02091414
- Testing
- mycophenolate mofetil (MMF), cyclosporine A (CsA), corticosteroids
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Heart Diseases, Heart Transplantation
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
The purpose of this study is to assess the safety and efficacy of tacrolimus in de novo heart transplantation.
- Trial name
- NCT00157014
- Testing
- Tacrolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 13 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Astellas Pharma Inc
Rejection Heart Transplant
Cardiac MRI and Cardiac Allograft Rejection
In this a prospective, blinded, collaboration study between pediatric and adult transplant departments. Cardiac MRI data on patient with heart transplantations will be collected during years 2020-2022.
- Trial name
- NCT04311346
- Testing
- Cardiac MR
- Where
- Finland
- Volunteers
- 72 people
- Sponsor
- Helsinki University Central Hospital
Heart Transplantation
Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection
The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans.
- Trial name
- NCT02300870
- Testing
- Optison
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital